Cas:59652-88-9 2,4,6-triethoxybenzaldehyde manufacturer & supplier

We serve Chemical Name:2,4,6-triethoxybenzaldehyde CAS:59652-88-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2,4,6-triethoxybenzaldehyde

Chemical Name:2,4,6-triethoxybenzaldehyde
CAS.NO:59652-88-9
Synonyms:2,4,6-triethoxy-benzaldehyde;2,4,6-triethoxybenzaldehyd;2,4,6-Triaethoxy-benzaldehyd;Benzaldehyde,2,4,6-triethoxy
Molecular Formula:C13H18O4
Molecular Weight:238.28000
HS Code:2912499000

Physical and Chemical Properties:
Melting point:98ºC
Boiling point:376.8ºC at 760 mmHg
Density:1.07g/cm3
Index of Refraction:1.513
PSA:44.76000
Exact Mass:238.12100
LogP:2.69520

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2,4,6-triethoxy-benzaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzaldehyde,2,4,6-triethoxy physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4,6-triethoxy-benzaldehyde Use and application,2,4,6-Triaethoxy-benzaldehyd technical grade,usp/ep/jp grade.


Related News: The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. 2,4,6-triethoxybenzaldehyde manufacturer Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’. 2,4,6-triethoxybenzaldehyde supplier Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’. 2,4,6-triethoxybenzaldehyde vendor For example, an active ingredient to relieve pain is included in a painkiller. 2,4,6-triethoxybenzaldehyde factory The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.